EUVIMEDEUVIMED entdecken
Crossref

Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits

Katarina D Kovacevic Miljević iD, Shuhao Zhu, James C Gilbert, Warren Harvey, Paul Tarantino, Bernd Jilma

Nucleic Acid Therapeutics · 2026

DOI: 10.1177/21593337261476421 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2026. Verfasst von Katarina D Kovacevic Miljević und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, von Willebrand Factor, Fetal Development, Embryonic Development. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Band Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rondaptivon pegol (BT200) is a PEGylated RNA aptamer that prolongs von Willebrand factor (VWF) and factor VIII half-lives in patients with hemophilia A and von Willebrand disease (VWD) type 2B. Embryo–fetal safety is particularly relevant given the disproportionate disease burden in women with VWD. Data on placental transfer and developmental safety of PEGylated aptamers remain limited. An embryo–fetal development study was conducted in pregnant rabbits. Animals received rondaptivon pegol subcutaneously (0, 1.5, 5, or 15 mg/kg/day) from gestational days (GDs) 7–19. Maternal toxicokinetic samples and pooled fetal plasma concentrations were collected during gestation to quantify transplacental exposure. Rondaptivon pegol was well tolerated, with no maternal toxicity, no effects on implantation, and no treatment-related fetal malformations. Dose-related reductions in mean fetal body weight (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, Nucleotidevon Willebrand FactorFetal DevelopmentEmbryonic Developmentvon Willebrand DiseasesHemophilia AAnimalsFemaleRabbitsPregnancyHumansPolyethylene GlycolsMaternal-Fetal ExchangeFactor VIIIPlacentaFetus

Stichwörter der Autor:innen

PEGylated aptamerembryo–fetal developmentplacental transfervon Willebrand factor

Substanzen

Aptamers, Nucleotidevon Willebrand FactorPolyethylene GlycolsFactor VIII

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Band Therapeutics LLC, Lexington, Massachusetts, USA.
  • ICON plc, Edinburgh, UK.
  • PMT Pharma Consulting, Worcester, Massachusetts, USA.

ORCID-Profile: Katarina D Kovacevic Miljević

Förderung

  • Band Therapeutics

Zitieren

APA

Kovacevic Miljević, K. D., Zhu, S., Gilbert, J. C., Harvey, W., Tarantino, P., & Jilma, B. (2026). Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337261476421

Vancouver

Kovacevic Miljević KD, Zhu S, Gilbert JC, Harvey W, Tarantino P, Jilma B. Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits. Nucleic Acid Therapeutics. 2026. doi:10.1177/21593337261476421

BibTeX
@article{KovacevicMiljevi2026,
  author = {Kovacevic Miljević, Katarina D and Zhu, Shuhao and Gilbert, James C and Harvey, Warren and Tarantino, Paul and Jilma, Bernd},
  title = {Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits},
  journal = {Nucleic Acid Therapeutics},
  year = {2026},
  doi = {10.1177/21593337261476421}
}
Kostenlos starten →